Notable progress has been made in understanding the complex genetic architecture of metabolic dysfunction-associated steatotic liver disease (MASLD). The increased availability of population-scale cohorts, combined with noninvasive liver fat quantification techniques such as MRI-based proton density fat fraction (PDFF), has enabled large-scale genome-wide association studies (GWAS). In a recent study, these approaches have identified novel loci such as
COBLL1 [
1], reinforcing the central role of glucose and lipid metabolism in MASLD pathogenesis. While heritability estimates for MASLD range from 25% to 50% [
2,
3], known GWAS variants account for only a modest proportion of this risk. This gap, often termed “missing heritability,” may result not only from the limited detection of small-effect variants but also from unmodeled gene–environment interactions and epigenetic regulation.
Obesity, a central driver of MASLD, has been shown to modify the penetrance of known genetic variants such as
PNPLA3 and
TM6SF2 on hepatic fat accumulation [
4]. As MASLD diagnostic criteria have evolved to explicitly incorporate cardiometabolic features [
5], incorporating physiological context into genetic analysis has become increasingly important.
In this context, Jamialahmadi et al. [
6] conducted a genome-wide environment interaction study (GEWIS) using data from over 378,000 individuals of European ancestry in the UK Biobank. Focusing on interactions between single nucleotide polymorphisms (SNPs) and body mass index (BMI), the study used serum alanine aminotransferase (ALT) as a proxy for liver injury and validated the findings in meta-analysis on PDFF. They identified 13 loci with significant SNP×BMI interactions. Among these were four novel loci—
GIPR, HLA, COBLL1, and
DPM3—in addition to several established MASLD-related variants including
PNPLA3 and
TM6SF2. The identification of previously established loci, including a context-dependent bidirectional effect at CYP7A1, highlights the robustness of the approach.
One of the most intriguing findings is an intronic variant in
GIPR (rs34783010-T), which showed complex associations: lower BMI yet higher HbA1c and liver triglyceride content. This variant was also associated with PDFF, and with increased odds of Alzheimer’s disease in phenomewide association analyses. These associations align with reduced circulating levels of gastric inhibitory polypeptide (GIP), implicating impaired receptor function or hormone clearance. The clinical relevance is underscored by the recent approval of tirzepatide—a dual
GIPR/GLP1R agonist—for treating obesity and type 2 diabetes [
7], and its efficacy in resolving MASH and improving liver fibrosis in the phase II trial [
8]. These results suggest that GIPR agonists may offer therapeutic benefit in genetically susceptible individuals, particularly those with MASLD manifesting under atypical metabolic profiles.
Another locus of interest lies between UBXN2B and CYP7A1. The lead SNP (rs7826120-T) exhibited a context-dependent effect: associated with increased ALT in obese individuals, but decreased ALT in lean individuals. This bidirectional interaction was confirmed in an independent PDFF cohort, indicating that the genotype’s impact is modulated by metabolic state. Fine-mapping and regulatory annotation prioritized rs10504255, a variant located within a liver-specific enhancer, as the likely functional driver. Transcription factor motif analysis showed altered binding potential for both activators (PPARG and HNF1A) and repressors (FOXA1 and REST), suggesting allele-specific transcriptional control. Importantly, CRISPR activation (CRISPRa) experiments in hepatocyte cell line demonstrated that the enhancer activation selectively increased CYP7A1 expression, prioritizing it—not UBXN2B—as the downstream effector gene.
This integrative framework—spanning GEWIS, fine-mapping, motif prediction, epigenomic annotation, and functional perturbation—suggests a rigorous approach for validating genomic findings from the study. Bridging statistical association with experimental validation, both in vitro and in vivo, reinforces the biological plausibility of the findings and strengthens their translational relevance.
Supporting this, phenome-wide association analyses of rs7826120 revealed links to elevated LDL and VLDL cholesterol, increased risk of gallstones and cardiovascular disease, and altered bile acid metabolites—traits consistent with impaired conversion of cholesterol into bile acids. To validate this mechanism in vivo, the authors used CRISPR/Cas9 gene editing in zebrafish to disrupt two orthologs of CYP7A1. In metabolically challenged larvae (fed excess calories with or without cholesterol), mutant fish showed significantly reduced liver fat compared to wild-type controls. No effect was observed in non-challenged conditions, indicating that the gene’s suggested role in hepatic steatosis can be conditional on metabolic stress.
Still, the direction of the effect in zebrafish differs from human data, where the risk allele is associated with increased liver fat. This discrepancy likely reflects speciesspecific physiology, developmental stage differences, or compensatory responses. In particular, zebrafish larvae at 10 days post-fertilization lacked substantial adipose tissue and exhibited incomplete bile acid regulatory circuits, complicating direct comparisons. Such divergence underscores the need for caution when translating experimental models into human pathology, and highlights the importance of complementary validation systems.
The context-sensitive nature of these gene–phenotype interactions holds important implications for clinical translation. If genetic variants such as those in CYP7A1 or GIPR exert differential effects depending on BMI or metabolic status, then uniform treatment strategies may yield heterogeneous outcomes. These findings argue for the incorporation of genetic background into therapeutic decisionmaking, particularly as targeted agents like GIPR agonists move into broader clinical use. Genotype-stratified trials may help determine which subgroups derive maximal benefit, especially in patients with lean MASLD or metabolically complicated obesity.
Taken together, this study identifies GIPR and CYP7A1 as key modulators of MASLD in the context of adiposity. It also illustrates the power of integrating large-scale genetic interaction studies with multi-layered functional validation to uncover biologically and clinically relevant pathways. As therapeutic options for MASLD remain limited, such genetically informed approaches offer a promising path forward toward precision hepatology and new target for MASLD.
FOOTNOTES
-
Authors’ contributions
Hyungtai Sim: writing-original draft. Murim Choi: writingoriginal draft.
-
Acknowledgements
This work was supported in part by the grants from the Korean Research Foundation (2021-NR056442) to Murim Choi.
-
Conflicts of Interest
The authors have no conflicts of interest to declare.
Abbreviations
genome-wide environment interaction study
gastric inhibitory polypeptide
genome-wide association studies
metabolic dysfunction-associated steatotic liver disease
proton density fat fraction
single nucleotide polymorphisms
REFERENCES
- 1. Chen Y, Du X, Kuppa A, Feitosa MF, Bielak LF, O’Connell JR, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 2023;55:1640-1650.
- 2. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149:1784-1793.
- 3. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
- 4. Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49:842-847.
- 5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966-1986.
- 6. Jamialahmadi O, Mujica E, Morris L, Mancina RM, Ciociola E, Qadri SF, et al. Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2025;31:1252-1268.
- 7. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.
- 8. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunctionassociated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299-310.
Citations
Citations to this article as recorded by
